Reversal of chemoresistance and enhancement of apoptosis by statins through down-regulation of the NF-κB pathway

Biochemical Pharmacology

Volumn 75, Issue 4, 2008, Pages 907-913

  Ahn, Kwang Seok ^a   Sethi, Gautam ^a   Aggarwal, Bharat B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Apoptosis; Chemotherapeutic agents; Nuclear factor kappaB; Simvastatin

Indexed keywords

ATORVASTATIN; COMPACTIN; DOXORUBICIN; FLUINDOSTATIN; FLUOROURACIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEVINOLIN; PACLITAXEL; PRAVASTATIN; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NF-KAPPA B; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 38649103825     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.10.010     Document Type: Article

References (27)

1. Pawelczyk T., Kloszewska I., and Sobow T. Statins-"21st century aspirin"?. Pol Merkuriusz Lek 19 (2005) 111-114
2. Miida T., Hirayama S., and Nakamura Y. Cholesterol-independent effects of statins and new therapeutic targets: ischemic stroke and dementia. J Atheroscler Thromb 11 (2004) 253-264
3. Gonyeau M.J. Statins and osteoporosis: a clinical review. Pharmacotherapy 25 (2005) 228-243
4. Brower V. Of cancer and cholesterol: studies elucidate anticancer mechanisms of statins. J Natl Cancer Inst 95 (2003) 844-846
5. Haffner S.M. Statin therapy for the treatment of diabetic dyslipidemia. Diabetes Metab Res Rev 19 (2003) 280-287
6. Ray J.G., Mamdani M., Tsuyuki R.T., Anderson D.R., Yeo E.L., and Laupacis A. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med 161 (2001) 1405-1410
7. Coogan P.F., Smith J., and Rosenberg L. Statin use and risk of colorectal cancer. J Natl Cancer Inst 99 (2007) 32-40
8. Agarwal B., Bhendwal S., Halmos B., Moss S.F., Ramey W.G., and Holt P.R. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 5 (1999) 2223-2229
9. Hoffmann P., Roumeguere T., Schulman C., and van Velthoven R. Use of statins and outcome of BCG treatment for bladder cancer. N Engl J Med 355 (2006) 2705-2707
10. Platz E.A., Leitzmann M.F., Visvanathan K., Rimm E.B., Stampfer M.J., Willett W.C., et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 98 (2006) 1819-1825
11. Bhuket T.P., and Higgins P.D. Drug insight: statins and gastrointestinal cancer. Nat Clin Pract Gastroenterol Hepatol 3 (2006) 552-562
12. Coogan P.F., Rosenberg L., and Strom B.L. Statin use and the risk of 10 cancers. Epidemiology 18 (2007) 213-219
13. Browning D.R., and Martin R.M. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 120 (2007) 833-843
14. Ahn K.S., Sethi G., and Aggarwal B.B. Simvastatin potentiates TNF-{alpha}-induced apoptosis through the down-regulation of NF-{kappa}B-dependent antiapoptotic gene products: role of I{kappa}B{alpha} kinase and TGF-beta-activated kinase-1. J Immunol 178 (2007) 2507-2516
15. Ahn K.S., and Aggarwal B.B. Transcription factor NF-{kappa}B: a sensor for smoke and stress signals. Ann N Y Acad Sci 1056 (2005) 218-233
16. Garg A., and Aggarwal B.B. Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia 16 (2002) 1053-1068
17. Bharti A.C., and Aggarwal B.B. Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol 64 (2002) 883-888
18. Sethi G., and Aggarwal B.B. Role of NF-kappaB and NF-kappaB-regulated gene products in chemoresistance and radioresistance. Curr Cancer Ther Rev 2 (2006) 115-125
19. Patel N.M., Nozaki S., Shortle N.H., Bhat-Nakshatri P., Newton T.R., Rice S., et al. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene 19 (2000) 4159-4169
20. Singh R.P., Mallikarjuna G.U., Sharma G., Dhanalakshmi S., Tyagi A.K., Chan D.C., et al. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance. Clin Cancer Res 10 (2004) 8641-8647
21. Chaturvedi M.M., Mukhopadhyay A., and Aggarwal B.B. Assay for redox-sensitive transcription factor. Methods Enzymol 319 (2000) 585-602
22. Ahn K.S., Sethi G., and Aggarwal B.B. Embelin an inhibitor of X chromosome-linked inhibitor-of-apoptosis protein, blocks nuclear factor-kappaB (NF-kappaB) signaling pathway leading to suppression of NF-kappaB-regulated antiapoptotic and metastatic gene products. Mol Pharmacol 71 (2007) 209-219
23. Giri D.K., and Aggarwal B.B. Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates. J Biol Chem 273 (1998) 14008-14014
24. Wong W.W., Dimitroulakos J., Minden M.D., and Penn L.Z. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16 (2002) 508-519
25. Sora M.K., Kruszewski A.A., Stokłosa T., Czyzyk J., Lasek W., Malejczyk J., et al. Synergistic antiproliferative activity of tumor necrosis factor alpha (TNF-alpha) and lovastatin. Arch Immunol Ther Exp (Warsz) 42 (1994) 269-274
26. Rasmussen L.M., Hansen P.R., Nabipour M.T., Olesen P., Kristiansen M.T., and Ledet T. Diverse effects of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells. Biochem J 360 (2001) 363-370
27. Hilgendorff A., Muth H., Parviz B., Staubitz A., Haberbosch W., Tillmanns H., et al. Statins differ in their ability to block NF-kappaB activation in human blood monocytes. Int J Clin Pharmacol Ther 41 (2003) 397-401